Captor Therapeutics S.A.

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratitoclax, a bifunctional MCL-1 protein degrader that is in the CTA-enabling stage for liquid and solid tumors; CT-02B, a NEK7 degrader that is in preclinical trials for neuroinflammation indications in Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS); CT-02S, a NEK7 degrader that is in preclinical trials for systemic autoimmunity indications in inflammatory bowel diseases (IBD), gout, and dermatological diseases; and CT-05, a PKCtheta degrader that is in preclinical trials for autoimmunity, transplantation, and metabolism indications. In addition, the company's candidates in the discovery phase include an undisclosed project for oncology, autoimmunity, CNS, and rare indications; and novel E3 ligases for oncology and autoimmunity indications. Captor Therapeutics Spolka Akcyjna was incorporated in 2015 and is headquartered in Wroclaw, Poland.